Csl Behring
Clinical trials sponsored by Csl Behring, explained in plain language.
Makes plasma-derived and recombinant therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New hope for cancer survivors: drug aims to shield against Life-Threatening infections
Disease control Not yet recruitingThis study tests a drug called IgPro20 in 63 adults who have a weakened immune system after receiving CAR T-cell therapy for blood cancers like lymphoma or multiple myeloma. The goal is to see if the drug can lower the number of serious bacterial infections, such as pneumonia or …
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a higher dose slow lung damage in Alpha-1 patients?
Disease control Not yet recruitingThis study tests whether higher doses of the drug Respreeza/Zemaira can slow lung damage better than the standard dose in adults with emphysema caused by Alpha-1 antitrypsin deficiency. About 270 participants will receive weekly IV infusions for 3 years. The goal is to find the o…
Phase: PHASE4 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC